A group of scientists from the Institute of Bioorganic Chemistry of the Academy of Sciences of the Republic of Uzbekistan has created an original drug Biomayrin 600 mg based on polygalacturonic acid (pectin) and anti-tuberculosis drugs – isoniazid, ethambutol and rifampicin.

It should be noted that tuberculosis is a disease that poses a threat to human health, and the second most lethal outcome among infectious diseases. According to WHO, every year about 10 million people around the world fall ill with tuberculosis, of which more than 1.5 million die. This figure has risen again as a result of the COVID-19 pandemic. In Uzbekistan, about 25,000 people get infected with tuberculosis every year.

Until now, no effective cure for tuberculosis has been invented. Most of the drugs used today were created half a century ago and have several drawbacks. Their side effects are so high that they cause additional illnesses during treatment.

Such drugs work in the body for no more than 3-6 hours and should be taken several times a day to maintain therapeutic concentration. This, in turn, causes various toxic-allergic conditions.

Biomayrin 600 mg, created by domestic scientists, has a macromolecular nature and is linked to the macromolecule of the natural polymer polygalacturonic acid by anti-tuberculosis chemical bonds of isoniazid, ethambutol and rifampicin. As a result, the side effects of other drugs against this disease have decreased several times, and the duration of effective action in the body has increased significantly.

The drug has a targeted effect on pathogenic cells and has a high level of resistance against various strains of tuberculosis.

UzA